

Dear Eye Care Professional,

We look forward to attending the American Academy of Ophthalmology (AAO) annual meeting in Chicago this week. Here's a preview of some of the Bausch + Lomb news we'll be highlighting; for more information on our data presentations and educational events, [click here](#).

The FDA has just [approved](#) the **enVista® Envy™ full range of vision IOL**, which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. Envy also enables surgeons to treat a wider range of astigmatic patients with more accuracy and precision with 0.5D steps (or less) throughout the cylinder range.



Please see indication and important safety information at the end of this letter.

We recently launched an educational website, www.KnowYourDryEye.com, to help consumers and patients better understand what dry eye is and how it can manifest. The content is based on a [survey](#) we conducted finding that many people don't understand their symptoms could be due to dry eye or that there are effective treatments available.



In September, we celebrated the **one-year launch anniversary of MIEBO®** (perfluorohexyloctane ophthalmic solution). To date, MIEBO has been prescribed to more than 150,000 patients by more than 15,000 doctors. We are holding an immersive event in New York's Times Square this week to encourage patients to ask their eye doctor about dry eye.



Please see indication and important safety information at the end of this letter.

We're **reaching out to dry eye patients where they are**. Actress and XIIDRA® (lifitegrast ophthalmic solution) 5% spokesperson Julie Bowen recently addressed dry eye and the importance of talking to an eye doctor on [The TODAY Show](#) and with several other prominent consumer-facing media outlets.



Please see indication and important safety information at the end of this letter.

Bausch + Lomb [recently acquired](#) Trukera Medical and its **ScoutPro® point-of-care portable device** for precisely measuring tear osmolarity to help surgeons meet their patients' high expectations by identifying hyperosmolarity, a key indicator of dry eye disease, prior to cataract or refractive procedures.



A group of retina experts [published](#) **core consensus guidelines to support standardization of suprachoroidal space (SCS) injection techniques**. XIPERE® (triamcinolone acetonide injectable suspension) is the first and only therapy available in the United States that utilizes the SCS to treat patients suffering from macular edema associated with uveitis.



Please see indication and important safety information at the end of this letter.

Data [published](#) by the NIH suggest that oral supplementation with vitamin C, vitamin E, and lutein/zeaxanthin may slow progression of non-central geographic atrophy in age-related macular degeneration (AMD). If confirmed, the findings of this study indicate that some patients with advanced AMD may benefit from an AREDS 2 vitamin formulation.¹



To learn more about these updates and other exciting Bausch + Lomb news, we invite you to visit us at booth #4826 during the meeting. If you aren't attending AAO, please reach out to your sales representative or our customer service team at 1-800-338-2020 for surgical products or 1-800-553-5340 for pharmaceutical products.

Sincerely,

A handwritten signature in black ink, appearing to read "Andrew Stewart".

Andrew Stewart
President, Global Pharmaceuticals and
International Consumer
Bausch + Lomb

A handwritten signature in black ink, appearing to read "Luc Bonnefoy".

Luc Bonnefoy
President, Surgical
Bausch + Lomb

enVista Envy toric and non-toric IOL Indications and Important Safety Information

Indications

The **enVista Envy hydrophobic acrylic IOL** is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia with less than

or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.

The **enVista Envy toric hydrophobic acrylic IOL** is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.

Warnings/Precautions

Physicians should weigh the potential risk/benefit ratio before implanting the enVista Envy lens under any of the circumstances or conditions outlined in the Instructions for Use labeling. Some visual disturbances may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or radial lines around point sources of light (starbursts) under nighttime conditions, glare, double vision, haziness and blurred vision. It is expected that, in a small percentage of patients, the observation of such phenomena will be annoying and may be perceived as a hindrance, particularly in low illumination conditions such as nighttime driving. As with other trifocal IOLs, there is a possibility that visual disturbances may be significant enough that the patient will request explant of the IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients, therefore, patients implanted with trifocal IOLs should exercise caution when driving at night or in low light or poor visibility conditions. Care should be taken to achieve IOL centration as IOL decentration may result in patients experiencing visual disturbances or suboptimal vision under certain lighting conditions. The surgeon must target emmetropia to achieve optimal visual performance. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). Please provide a copy of the Patient Information Brochure, which can be found at www.bausch.com/IFU. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs earlier in its progression than patients with monofocal IOLs. This may be due to the reduced contrast sensitivity observed with multifocal IOLs.

Additional Precautions for Toric IOLs: The enVista Envy Toric IOL has not been evaluated in a clinical study. In general, astigmatism that is corrected with a higher cylinder power IOL can result in clinically significant residual astigmatism. The effect of residual astigmatism at distance, intermediate, and near was evaluated in a clinical study of patients who had been implanted with non-toric enVista Envy IOLs and were induced with cylinder power to simulate various levels of residual astigmatism. If a secondary surgical intervention is necessary to reposition the IOL, explantation should be considered as some patients may have recurrent or persistent issues related to rotational instability and misalignment.

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

ATTENTION: See the Directions for Use for a complete listing of indications and important safety information.

WHAT IS MIEBO?

INDICATION

MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

- Patients should remove contact lenses before using MIEBO™ and wait for at least 30 minutes before reinserting.
- It is important for patients to use MIEBO exactly as prescribed.
- It is not known if MIEBO™ is safe and effective in children under the age of 18.
- The most common eye side effect seen in studies was blurred vision (1% to 3% of patients reported blurred vision and eye redness).

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click [here](#) for full Prescribing Information for MIEBO.

WHAT IS XIIDRA?

XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Do not use XIIDRA if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.

The most common side effects of XIIDRA include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation.

To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using XIIDRA and wait for at least 15 minutes before placing them back in your eyes. It is not known if XIIDRA is safe and effective in children under 17 years of age.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click [here](#) for full Prescribing Information for XIIDRA.

WHAT IS XIPERE?

INDICATION

XIPERE (triamcinolone acetonide injectable suspension) is a corticosteroid used to treat macular edema associated with an eye disease called uveitis.

IMPORTANT SAFETY INFORMATION

- Your eye doctor will monitor you for elevated eye pressure following treatment and manage it with medication or surgery if required.
- See your eye doctor right away if your eyes become red, sensitive to light or painful, or if you notice changes in vision.
- XIPIRE® is not appropriate for use in patients with eye infections. It should be used with caution in patients with a history of herpes simplex in the eye.
- XIPIRE® is not appropriate for use in patients with a known allergy to triamcinolone acetonide or any other components of this product.
- Use of corticosteroids such as XIPIRE® may produce cataracts, increased eye pressure and glaucoma, and may increase the likelihood of eye infections.
- Patients being treated with XIPIRE® for extended periods of time will be monitored for problems with the body's hormonal system, which controls the ability to respond to stress.
- In clinical studies, the most common eye-related side effects were increased eye pressure and eye pain. Other side effects included cataract, floaters or flashes of light, injection site pain, burst blood vessels, reduced or blurred vision, dry eye, light sensitivity, redness, infection, swelling, watery eyes, eye or eyelid irritation, bumps on the eyelid, itchy eyes, and drooping eyelid.
The most common non-eye-related side effect was headache.
- Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant. Talk to your eye doctor.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click [here](#) for full Prescribing Information for XIPIRE.

References

1. Keenan TDL, Agrón E, Keane PA, et al. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. *Ophthalmology*. Published online July 16, 2024. doi:10.1016/j.optha.2024.07.014

XIPIRE® is a trademark of Clearside Biomedical, Inc. used under license.

© 2024 Bausch + Lomb.

MTB.0424.USA.24.
